BR112014014341A2 - Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica - Google Patents

Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica

Info

Publication number
BR112014014341A2
BR112014014341A2 BR112014014341A BR112014014341A BR112014014341A2 BR 112014014341 A2 BR112014014341 A2 BR 112014014341A2 BR 112014014341 A BR112014014341 A BR 112014014341A BR 112014014341 A BR112014014341 A BR 112014014341A BR 112014014341 A2 BR112014014341 A2 BR 112014014341A2
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical composition
methyl intermediate
methyl
composition
Prior art date
Application number
BR112014014341A
Other languages
English (en)
Inventor
Russo Domenico
Erno Kiss Laszlo
Bruno Reis Wahnon Jorge
Alexander Learmonth David
Eszenyi Tibor
Zimmermann Axel
Schlummer Bjoern
Kreis Michael
Reiter Klaus
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1121413.7A external-priority patent/GB201121413D0/en
Priority claimed from GBGB1201758.8A external-priority patent/GB201201758D0/en
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of BR112014014341A2 publication Critical patent/BR112014014341A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

INTERMEDIÁRIO METILADO, SEU MÉTODO DE PREPARAÇÃO E SEUS USOS, E COMPOSIÇÃO FARMACÊUTICA. A presente invenção refere-se a um intermediário metilado que pode ser desmetilado para proporcionar um inibidor de catecol-O- metiltransferase útil no tratamento da doença de Parkinson, uma composição farmacêutica em forma de dosagem unitária para administração oral compreendendo o referido composto, uso do mesmo na preparação da referida composição, bem como métodos de preparação e utilização do referido intermediário.
BR112014014341A 2011-12-13 2012-12-12 Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica BR112014014341A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161570141P 2011-12-13 2011-12-13
GBGB1121413.7A GB201121413D0 (en) 2011-12-13 2011-12-13 Chemical compounds and processes
US201261593625P 2012-02-01 2012-02-01
GBGB1201758.8A GB201201758D0 (en) 2012-02-01 2012-02-01 Chemical compounds and processes
US201261718589P 2012-10-25 2012-10-25
PCT/PT2012/000048 WO2013089573A1 (en) 2011-12-13 2012-12-12 Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor

Publications (1)

Publication Number Publication Date
BR112014014341A2 true BR112014014341A2 (pt) 2017-08-22

Family

ID=48612903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014341A BR112014014341A2 (pt) 2011-12-13 2012-12-12 Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica

Country Status (15)

Country Link
US (2) US9126988B2 (pt)
EP (2) EP3604299B1 (pt)
JP (3) JP6456143B2 (pt)
BR (1) BR112014014341A2 (pt)
CA (2) CA3088684C (pt)
CY (1) CY1122580T1 (pt)
DK (1) DK2791134T3 (pt)
ES (2) ES2758659T3 (pt)
HR (1) HRP20192133T8 (pt)
HU (1) HUE047856T2 (pt)
PL (1) PL2791134T3 (pt)
PT (2) PT2791134T (pt)
RS (1) RS59666B1 (pt)
SI (1) SI2791134T1 (pt)
WO (1) WO2013089573A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168793B2 (en) 2005-07-26 2012-05-01 Portela & Ca., S.A. Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PT2481410T (pt) 2007-01-31 2016-10-18 BIAL-PORTELA & Cª S A Derivados de nitrocatecóis como inibidores da comt administrados num regime posológico específico
EP2276758B1 (en) 2008-03-17 2016-01-06 Bial-Portela & CA, S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol
KR20120027197A (ko) 2009-04-01 2012-03-21 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CA3088684C (en) 2011-12-13 2021-10-26 Bial - Portela & C.A., S.A. Compound 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol in microparticulate form and its use in the treatment of parkinson's disease
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
GB2563858A (en) * 2017-06-27 2019-01-02 Azad Pharmaceutical Ingredients Ag New route of synthesis for opicapone
US20210087183A1 (en) * 2017-12-18 2021-03-25 Unichem Laboratories Ltd Process for the preparation of opicapone and intermediates thereof
EP3860602A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
EP3860603A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
CN109529881A (zh) * 2018-11-12 2019-03-29 刘晓菊 一种治疗帕金森药物用中间体5-硝基香草酸的制备方法
KR20220154182A (ko) * 2020-03-13 2022-11-21 바이알 - 포르텔라 앤드 씨에이 에스에이 미분화 오피카폰
GB202011709D0 (en) 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
GB202016425D0 (en) 2020-10-16 2020-12-02 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
CN112375014A (zh) * 2020-12-17 2021-02-19 重庆柳江医药科技有限公司 一种奥匹卡朋工艺杂质及制备方法和用途
KR20230118933A (ko) 2020-12-17 2023-08-14 바이알 - 포르텔라 앤드 씨에이 에스에이 초기 특발성 파킨슨병에 대한 치료 요법
WO2022180649A1 (en) * 2021-02-26 2022-09-01 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
CN113292489B (zh) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 二氯代二烷基烟腈的制备方法
GB202204798D0 (en) 2022-04-01 2022-05-18 Bial Portela & Ca Sa Prodrugs of opicapone
GB202212082D0 (en) 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) 1921-07-25 1925-04-07 Louis A Godbold Lubricator
FR1260080A (fr) 1960-03-22 1961-05-05 Materiel De Forage Soc De Fab Trépan à molettes étanche
IL31990A (en) 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4264573A (en) 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4386668A (en) 1980-09-19 1983-06-07 Hughes Tool Company Sealed lubricated and air cooled rock bit bearing
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
DE3840954A1 (de) 1988-12-05 1990-06-07 Shell Int Research Herstellung von 2-chlornicotinsaeureestern
US5206372A (en) 1990-06-05 1993-04-27 Shell Research Limited Preparation of 2-chloropyridine derivatives
EP0487774B1 (en) 1990-11-29 1994-10-26 Wei Ming Pharmaceutical Mfg. Co. Ltd. A direct tabletting auxiliary
US5622976A (en) 1991-12-31 1997-04-22 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2730322B1 (fr) 1995-02-02 1997-04-30 Imago Monture de lunettes metallique
DE19628617A1 (de) 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
US6206110B1 (en) 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
JP2002526482A (ja) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
SK2512002A3 (en) 1999-08-19 2002-07-02 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
FI20000635A0 (fi) 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
GB2363792A (en) 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
CN1166626C (zh) 2000-08-30 2004-09-15 李凌松 三或四取代苯基化合物、其制备方法及应用
US20030027253A1 (en) 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
EP1679313A3 (en) 2001-02-21 2006-08-16 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20030187007A1 (en) 2001-05-30 2003-10-02 Cao Sheldon Xiaodong Inhibitors of protein kinase for the treatment of disease
JP2005504014A (ja) 2001-06-08 2005-02-10 サイトビア インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法
EP1408964B1 (en) 2001-07-26 2007-01-24 MERCK PATENT GmbH Use of 2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl|-chromane and its physiologically acceptable salts
JP4379853B2 (ja) 2001-10-05 2009-12-09 惠民製藥股▲分▼有限公司 直接錠剤化用調合物および補助剤の調合方法
CN100364531C (zh) 2002-12-18 2008-01-30 西托维亚公司 3,5－二取代－[1,2,4]－二唑及类似物和其用途
WO2005006945A2 (en) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
PE20050338A1 (es) 2003-08-06 2005-05-16 Vertex Pharma Compuestos de aminotriazoles como inhibidores de proteina quinasas
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7300406B2 (en) 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1751133B1 (en) 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
WO2006061697A1 (en) 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
WO2006071184A1 (en) 2004-12-28 2006-07-06 Astrazeneca Ab Aryl sulphonamide modulators
US20080051441A1 (en) 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
KR20080000622A (ko) 2005-04-26 2008-01-02 뉴로서치 에이/에스 신규한 옥사디아졸 유도체 및 이의 의학적 용도
US20060257473A1 (en) 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2006132914A2 (en) 2005-06-03 2006-12-14 Abbott Laboratories Cyclobutyl amine derivatives
JP2007024970A (ja) 2005-07-12 2007-02-01 Miyakawa:Kk 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置
US20090000437A1 (en) 2005-07-14 2009-01-01 Provo Craft And Novelty, Inc. Methods for Cutting
US8168793B2 (en) 2005-07-26 2012-05-01 Portela & Ca., S.A. Nitrocatechol derivatives as COMT inhibitors
FR2889525A1 (fr) 2005-08-04 2007-02-09 Palumed Sa Nouveaux derives de polyquinoleines et leur utilisation therapeutique.
US20070048384A1 (en) 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
US20090111778A1 (en) 2005-11-18 2009-04-30 Richard Apodaca 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase
EP1956013B1 (en) 2005-11-30 2016-04-13 Fujifilm RI Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
PT2481410T (pt) 2007-01-31 2016-10-18 BIAL-PORTELA & Cª S A Derivados de nitrocatecóis como inibidores da comt administrados num regime posológico específico
ES2748599T3 (es) 2007-08-27 2020-03-17 Dart Neuroscience Cayman Ltd Compuestos terapéuticos de isoxazol
BRPI0908340A2 (pt) 2008-02-28 2018-12-26 Bial Portela & Ca Sa composição farmacêutica para fármacos pouco solúveis
EP2276758B1 (en) * 2008-03-17 2016-01-06 Bial-Portela & CA, S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol
BRPI0913913A2 (pt) 2008-07-29 2015-10-13 Bial Portela & Ca Sa regime de dosagem para nitrocatecóis
KR20120027197A (ko) 2009-04-01 2012-03-21 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
CN105816456A (zh) 2009-04-01 2016-08-03 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CA3088684C (en) * 2011-12-13 2021-10-26 Bial - Portela & C.A., S.A. Compound 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol in microparticulate form and its use in the treatment of parkinson's disease

Also Published As

Publication number Publication date
EP3604299A1 (en) 2020-02-05
PT2791134T (pt) 2019-12-18
PT3604299T (pt) 2023-10-31
JP2015500335A (ja) 2015-01-05
JP6456143B2 (ja) 2019-01-23
EP2791134A1 (en) 2014-10-22
CA3088684C (en) 2021-10-26
HUE047856T2 (hu) 2020-05-28
PL2791134T3 (pl) 2020-03-31
CA3088684A1 (en) 2013-06-20
ES2758659T3 (es) 2020-05-06
US9126988B2 (en) 2015-09-08
EP3604299B1 (en) 2023-07-26
CA2858025C (en) 2020-09-22
JP6721558B2 (ja) 2020-07-15
US20160009700A1 (en) 2016-01-14
RS59666B1 (sr) 2020-01-31
US9630955B2 (en) 2017-04-25
JP2020059729A (ja) 2020-04-16
DK2791134T3 (da) 2019-12-09
US20140350057A1 (en) 2014-11-27
CA2858025A1 (en) 2013-06-20
CY1122580T1 (el) 2021-01-27
SI2791134T1 (sl) 2020-01-31
WO2013089573A1 (en) 2013-06-20
HRP20192133T8 (hr) 2021-02-19
EP2791134B1 (en) 2019-09-25
JP2018052949A (ja) 2018-04-05
HRP20192133T1 (hr) 2020-02-21
ES2960805T3 (es) 2024-03-06

Similar Documents

Publication Publication Date Title
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BR112013000537A2 (pt) composição aquosa contendo bromexina
BR112014000371A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
BR112012023021A2 (pt) compostos de indazol e seus usos
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
BR112014003198A2 (pt) compostos para o tratamento e profilaxia de doença por vírus sincicial respiratório
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
ECSP13013011A (es) Triazolopiridinas
BR112014012628A2 (pt) di-hidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
UY31922A (es) Compuestos
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
BR112014002245A2 (pt) derivados de piridin-2(1h)-ona como inibidores de jak
BR112012006172A2 (pt) derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
RS53783B1 (en) INHALATION MEDICINAL PRODUCTS INCLUDING TIOTROPIUM
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
BR112014004732A2 (pt) composto benzotiazolona
BRPI1011851A2 (pt) Composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, epara tratar uma doença

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]